schizandrer a has been researched along with Liver Cirrhosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Che, J; Chen, J; Cui, K; Li, H; Sun, J; Wang, C; Wang, H; Zhuang, W | 1 |
| Liu, CH; Lv, J; Tao, YY; Zhao, ZM; Zhu, CW | 1 |
| Liu, CH; Liu, S; Tao, YY; Yang, T; Zheng, TH | 1 |
3 other study(ies) available for schizandrer a and Liver Cirrhosis
| Article | Year |
|---|---|
Schisantherin A ameliorates liver fibrosis through TGF-β1mediated activation of TAK1/MAPK and NF-κB pathways in vitro and in vivo.
Topics: Animals; Cell Line; Cyclooctanes; Cytokines; Dioxoles; Hepatic Stellate Cells; Lignans; Liver Cirrhosis; Male; MAP Kinase Kinase Kinases; Mice, Inbred ICR; Mitogen-Activated Protein Kinases; NF-kappa B; Rats; Signal Transduction; Thioacetamide; Transforming Growth Factor beta1 | 2021 |
[Effect of schisantherin A inhibit liver sinusoid endothelial cell function and action against liver fibrosis relating to angiogenesis].
Topics: Angiogenesis Inhibitors; Animals; Capillaries; Cell Movement; Cell Proliferation; Cyclooctanes; Dioxoles; Endothelial Cells; Humans; Lignans; Liver; Liver Cirrhosis; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor A; Zebrafish | 2016 |
Comparative pharmacokinetics and tissue distribution profiles of lignan components in normal and hepatic fibrosis rats after oral administration of Fuzheng Huayu recipe.
Topics: Administration, Oral; Animals; Cyclooctanes; Dioxoles; Drugs, Chinese Herbal; Kidney; Lignans; Liver; Liver Cirrhosis; Male; Polycyclic Compounds; Rats; Rats, Wistar; Tissue Distribution | 2015 |